Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA HONOR AWARDS: TYLENOL TAMPERING INVESTIGATION GROUP

Executive Summary

FDA HONOR AWARDS: TYLENOL TAMPERING INVESTIGATION GROUP is one of 36 groups or individuals receiving FDA's "Award of Merit," the agency's highest honor award. The Tylenol tampering group, which consists of five investigators from the Baltimore, Dallas, Philadelphia and San Juan districts, was given the award for "unique and exceptional investigation and reporting of a manufacturing and distribution system as a follow-up to a tampering emergency." The Tylenol group was among many groups and individuals to be acknowledged at the July 10 awards ceremony for their efforts against tampering. FDA Ohio District Office Research Center Director Frederick Fricke, for example, received an HHS "Distinguished Service Award" for "leadership and outstanding scientific achievements in the application of elemental analysis to the forensic evaluation of product tampering cases." P-A President James Cope, Young, Rubicam's Arthur Klein and the Council on Family Health's Frazier Cheston received a "Commissioner's Special Citation" award for their roles in developing a public service announcement on "Simple Precautions Against Tampering." The tampering radio spot began airing in August 1986 ("The Pink Sheet" Aug. 11, T&G-4). In addition to tampering, AIDS drug review, the Action Plan, and Reye Syndrome work were highlighted among the 200-plus FDA awards. FDA's OTC division received a "Group Recognition Award" for "sustained high performance, resourcefulness, and dedication in preparation of monographs for regulation of the OTC industry in the U.S." FDA's Office of Public Affairs received the same award for "exemplary public service on health hazard fronts alerting America's consumers of a record number of product recalls and tamperings in a timely fashion." Awards issued by PHS included a "Superior Service Award" to FDA Center for Drugs and Biologics Acting Director Paul Parkman, MD, "for exceptional management and leadership of the Center's . . . AIDS biologics program and effective participation on the PHS AIDS Task Force," and an "Outstanding Unit Citation" to FDA Virology Division Director Gerald Quinnan, MD, and "Special Recognition" awards to Biological IND Division Acting Director Donald Burlington, MD, and Division of Biometrics' William Fairweather, PhD, for their "outstanding effort[s] in conducting an epidemiologic study which helped resolve the Reye Syndrome controversy and significantly reduced the incidence of the disease." FDA Commissioner Young also received a PHS "Commissioned Corps Meritorious Service Medal" for "Exceptional achievement in leading the FDA to significant improvements in protecting the Nation's public health. Deputy Commissioner Norris was given an FDA "Award of Merit" for "exceptional dedication and contributions to the public health of the Nation, both from a national and international perspective."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel